9780792309451 - from clone to clinic (developments in biotherapy) (5 Ergebnisse)
- Hardcover
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes KönigreichRia Christie Collections
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 129,01
EUR 14,01 VersandVersand von Vereinigtes Königreich nach USAAnzahl: Mehr als 20 verfügbar
Zustand: New. In.
- Hardcover
Anbieter: Zubal-Books, Since 1961, Cleveland, OH, USAZubal-Books, Since 1961
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Gebraucht - Befriedigend
EUR 164,17
EUR 3,89 VersandVersand innerhalb von USAAnzahl: 1 verfügbar
Zustand: Good. *Price HAS BEEN REDUCED by 10% until Monday, August 17 (SALE item)* 356 pp., Hardcover, ex library else text clean and binding tight. - If you are reading this, this item is actually (physically) in our stock and ready for shipment once ordered. We are not bookjackers. Buyer is responsible for any additional dutie…s, taxes, or fees required by recipient's country. Photos available upon request.
- Hardcover
Anbieter: Revaluation Books, Exeter, Vereinigtes KönigreichRevaluation Books
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 170,33
EUR 14,62 VersandVersand von Vereinigtes Königreich nach USAAnzahl: 2 verfügbar
Hardcover. Zustand: Brand New. 400 pages. 9.21x6.14x0.88 inches. In Stock.
- Hardcover
Anbieter: moluna, Greven, Deutschlandmoluna
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 141,39
EUR 48,99 VersandVersand von Deutschland nach USAAnzahl: Mehr als 20 verfügbar
Zustand: New.
- Hardcover
Anbieter: AHA-BUCH GmbH, Einbeck, DeutschlandAHA-BUCH GmbH
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 201,39
EUR 63,82 VersandVersand von Deutschland nach USAAnzahl: 2 verfügbar
Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - One: Registration, Toxicity and Quality Control.- 1. Toxicity testing of rDNA products.- 2. Experiences with the EC 'high tech' procedure.- 3. The regulation of pharmaceuticals: philosophy and principles.- 4. Quality control of vaccines.- 5. Regulatory affa…irs and biotechnology in Europe: the CPMP 'high tech' and multistate procedures.- 6. Formulating biotechnology products.- 7. Development of analytical methods for monitoring the stability of antibody formation by hybridoma cells in continuous culture systems.- Two: Monoclonal Antibodies.- 8. Toward human monoclonal antibodies.- 9. Biodistribution, binding and internalisation of monoclonal antibodies to human ovarian carcinoma cells.- 10. Pharmacokinetics and tissue distribution of Indium-111-labeled OV-TL 3 F(ab')2 in ovarian cancer patients.- 11. Characterization of human monoclonal antibodies specific for the rabies virus.- 12. Biochemical and immunological evaluation of an anti-fibrin monoclonal antibody complex containing T2Gls Fab' intended for imaging venous thrombi.- 13. Monoclonal antibodies in radioimmunoscintigraphy. Some hurdles between clone and clinic.- 14. Clinical relevance of the tumor marker CA 15.3 in the management of cancer patients.- 15. Practical applications of monoclonal antibodies against polymorphic epithelial mucin in the differential diagnosis of human tumors.- 16. Selection of monoclonal anti-digoxin antibodies suitable for monitoring of cardiac glycosides.- 17. Diagnostic use of anti-modified nucleoside monoclonal antibodies.- 18. Monoclonal antibodies radiolabeled with different radioisotopes for biodistribution and radioimmunodetection of tumor xenografts in the nude rat.- 19. Bispecific monoclonal antibody (BIAB)-retargeted cellular therapy for local treatment of cancer patients.- 20. Enhanced binding of t-PA to fibrin using bispecific monoclonal antibodies.- 21. Recent developments and perspectives on the future of human and murine monoclonal antibodies in the diagnosis and treatment of cancer.- 22. Pharmacokinetics and safety of a human IGM antibody, HA-1A.- 23. Development and clinical experience with humanised monoclonal antibodies.- 24. A method for the transformation of hybridoma cell lines with improved efficiency: its use in the production of bispecific monoclonal antibodies.- 25. To an optimal design of an airlift bioreactor for the cultivation of hybridomas.- Three: Marketed Products.- 26. Experience with marketed biotech products: rt-PA.- 27. Clinical trial of recombinant human IL-2 in the treatment of Mycobacterium Avium complex infection.- 28. Use of recombinant human erythropoietin in anemic dialysis patients.- 29. Experience with biosynthetic growth hormone.- Four: New Products.- 30. Recombinant follicle stimulating hormone. I. Construction, selection and characterization of a cell line.- 31. Recombinant human follicle stimulating hormone. II. Biochemical and biological characteristics.- 32. Heterologous expression of human Interleukin-3.- 33. Purification of recombinant human Interleukin-3 from Bacillus Licheniformis.- 34. The acid- and thermolabile interferon alpha: a subtype, or a new cell inhibitor .- 35. The IFN receptor as tool for the discovery of new immunomodulatory drugs.- 36. Cloned receptors and transfected cell lines in the design of new drugs: muscarinic cholinergic receptors.- Five: Drug Delivery.- 37. Structural analysis of carbohydrate chains of native and recombinant-DNA glycoproteins.- 38. The role of protein structure in surface tension kinetics.- 39. Antigen carriers: a success determining factor for subunit vaccines .- 40. Intranasal delivery of insulin: absorption enhancement by the fusidate derivative STDHF in rabbits and rats and effects on human nasal ciliary movement in vitro.- 41. Improved oral peptide delivery by means of mucoadhesion.- 42. Delivery of therapeutic peptides and proteins.- 43. Compatibility studies of a soluble T4 receptor with a mi.
